指南与共识湿疹皮炎与荨麻疹

手部湿疹试验核心领域共识:体征、症状、控制与生活质量

Consensus on core domains for hand eczema trials: Signs, symptoms, control and quality of life.
指南 / 共识 · J Eur Acad Dermatol Venereol · 2025-04-25

2024年通过两轮在线德尔菲调查(第一轮208人、第二轮134人)及混合共识会议,国际手部湿疹专家达成共识,将手部湿疹的体征、症状、生活质量及随时间控制作为核心评估领域,并确定相应子领域,旨在统一未来治疗试验的结局指标。

要点

  • 核心领域包括体征(5个子领域)、症状(2个)、生活质量(4个)、随时间控制(4个)。
  • 脱屑/鳞屑和情绪影响/心理健康两个子领域仍存争议。
  • 皮肤屏障功能和患者报告治疗体验及28个子领域不纳入核心结局集。

核心结论

  • 未来手部湿疹治疗试验应测量体征、症状、生活质量和随时间控制作为核心结局领域,以产生可比较和有意义的結果。

主要发现

  • 共识纳入核心领域:手部湿疹体征(含5个核心子领域)、症状(2个子领域)、生活质量(4个子领域)、随时间控制(4个子领域)。
  • 子领域「脱屑/鳞屑」和「情绪影响/心理健康」仍存争议。
  • 共识决定「皮肤屏障功能」和「患者报告治疗体验」及28个子领域不纳入核心结局集。

关键数值与推荐

  • 德尔菲调查中,≥80%参与者评为「至关重要」的领域/子领域纳入核心集;≤50%同意则排除;50%至80%视为有争议需进一步讨论。

临床怎么用

  • 临床医生在评估手部湿疹治疗效果时,应关注体征、症状、生活质量及随时间控制等核心领域。

局限性

  • 脱屑/鳞屑和情绪影响/心理健康两个子领域仍存争议,需进一步讨论。
  • 下一步需确定合适的测量工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hand eczema (HE) is a common and complex skin disease. A uniform set of core outcomes and related measures for use in clinical trials is lacking, making it difficult to compare results across HE studies. OBJECTIVE: To reach consensus on a set of core domains and subdomains that should be measured in future therapeutic HE trials. METHODS: In 2024, we conducted a two-round online Delphi (eDelphi) survey among international HE experts, including physicians, patients and their relatives, researchers and industry representatives. A domain/subdomain was included in the core set when ≥80% of participants rated is as 'critically important'; 50% agreement or less resulted in its exclusion. Results from 50% to 80% were deemed controversial and subject for further discussion. During a hybrid consensus meeting, the stakeholders reviewed, completed and, if necessary, revised the preliminary eDelphi consensus. RESULTS: In the first and second round of the eDelphi, 208 and 134 persons, respectively, participated. Forty participants from 18 countries attended the consensus meeting. Consensus was reached to include the core domains 'signs of HE' (with five core subdomains), 'symptoms of HE' (two subdomains), 'HE-related quality of life' (four subdomains) and 'HE control over time' (four subdomains). The subdomains 'desquamation/scaling' and 'emotional impact/mental health' remained controversial. Consensus was reached that the domains 'skin barrier function' and 'patient-reported treatment experience' and 28 subdomains should not be part of the core outcome set. CONCLUSIONS: To produce comparable and meaningful results, future trials evaluating the effectiveness of HE treatments should measure signs and symptoms of HE, HE-related quality of life and HE control over time as core outcome domains. The next step of the HE core outcome set initiative (HECOS) is to identify appropriate measurement instruments.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Rönsch H, Drewitz KP, Atwater AR, et al. Consensus on core domains for hand eczema trials: Signs, symptoms, control and quality of life. J Eur Acad Dermatol Venereol. 2025. PMID: 40276953. doi:10.1111/jdv.20671

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。